{"id":"https://openalex.org/W1994057917","doi":"https://doi.org/10.1517/17425250802522188","title":"Role of flavin-containing monooxgenase in drug development","display_name":"Role of flavin-containing monooxgenase in drug development","alternate_titles":[],"publication_year":2008,"publication_date":"2008-11-12","ids":{"openalex":"https://openalex.org/W1994057917","doi":"https://doi.org/10.1517/17425250802522188","mag":"1994057917","pmid":"https://pubmed.ncbi.nlm.nih.gov/19040327"},"language":"en","primary_location":{"id":"doi:10.1517/17425250802522188","doi":"https://doi.org/10.1517/17425250802522188","is_oa":false,"landing_page_url":"https://doi.org/10.1517/17425250802522188","pdf_url":null,"source":{"id":"https://openalex.org/S102336391","display_name":"Expert Opinion on Drug Metabolism & Toxicology","issn_l":"1742-5255","issn":["1742-5255","1744-7607"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Drug Metabolism &amp; Toxicology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1994057917"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5028469156","display_name":"John Richard Cashman","orcid":"https://orcid.org/0000-0002-8628-9129","observed_orcids":["https://orcid.org/0000-0002-8628-9129"]},"institutions":[{"id":"https://openalex.org/I4210110847","display_name":"Human BioMolecular Research Institute","ror":"https://ror.org/018m20m74","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210110847"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"John R Cashman","raw_affiliation_strings":["Human BioMolecular Research Institute, 5310 Eastgate Mall, San Diego, CA 92121, USA. JCashman@HBRI.org"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Human BioMolecular Research Institute, 5310 Eastgate Mall, San Diego, CA 92121, USA. JCashman@HBRI.org","institution_ids":["https://openalex.org/I4210110847"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5028469156"],"corresponding_institution_ids":["https://openalex.org/I4210110847"],"apc_list":null,"apc_paid":null,"fwci":0.5407,"has_fulltext":false,"cited_by_count":80,"citation_normalized_percentile":{"value":0.32234432,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":99},"biblio":{"volume":"4","issue":"12","first_page":"1507","last_page":"1521"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11465","display_name":"Drug-Induced Hepatotoxicity and Protection","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/flavin-containing-monooxygenase","display_name":"flavin-containing monooxygenase","score":0.9980000257492065},{"id":"https://openalex.org/keywords/fmo","display_name":"FMO","score":0.7789999842643738},{"id":"https://openalex.org/keywords/drug-metabolism","display_name":"drug metabolism","score":0.7889999747276306},{"id":"https://openalex.org/keywords/preclinical-drug-development","display_name":"preclinical drug development","score":0.8790000081062317},{"id":"https://openalex.org/keywords/cytochrome-p450","display_name":"cytochrome P450","score":0.9480000138282776},{"id":"https://openalex.org/keywords/in-vivo-metabolism","display_name":"in vivo metabolism","score":0.8119999766349792},{"id":"https://openalex.org/keywords/small-animal-models","display_name":"small animal models","score":0.8069999814033508},{"id":"https://openalex.org/keywords/drug-design","display_name":"drug design","score":0.46799999475479126}],"concepts":[{"id":"https://openalex.org/C2776146729","wikidata":"https://www.wikidata.org/wiki/Q3860935","display_name":"Flavin-containing monooxygenase","level":5,"score":0.8471282124519348},{"id":"https://openalex.org/C13002179","wikidata":"https://www.wikidata.org/wiki/Q6901821","display_name":"Monooxygenase","level":4,"score":0.7040109038352966},{"id":"https://openalex.org/C33093398","wikidata":"https://www.wikidata.org/wiki/Q174337","display_name":"Flavin group","level":3,"score":0.6201573610305786},{"id":"https://openalex.org/C526171541","wikidata":"https://www.wikidata.org/wiki/Q407693","display_name":"Cytochrome P450","level":3,"score":0.6135452389717102},{"id":"https://openalex.org/C89311334","wikidata":"https://www.wikidata.org/wiki/Q1124842","display_name":"Drug metabolism","level":3,"score":0.5793404579162598},{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.5150578022003174},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.48519137501716614},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4705878794193268},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.4685424566268921},{"id":"https://openalex.org/C62231903","wikidata":"https://www.wikidata.org/wiki/Q1057","display_name":"Metabolism","level":2,"score":0.4408157467842102},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.41238734126091003},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.38606250286102295},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3337186574935913},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.32602494955062866}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004353","descriptor_name":"Drug Evaluation, Preclinical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010105","descriptor_name":"Oxygenases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D015394","descriptor_name":"Molecular Structure","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015507","descriptor_name":"Drugs, Investigational","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D015507","descriptor_name":"Drugs, Investigational","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1517/17425250802522188","doi":"https://doi.org/10.1517/17425250802522188","is_oa":false,"landing_page_url":"https://doi.org/10.1517/17425250802522188","pdf_url":null,"source":{"id":"https://openalex.org/S102336391","display_name":"Expert Opinion on Drug Metabolism & Toxicology","issn_l":"1742-5255","issn":["1742-5255","1744-7607"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Drug Metabolism &amp; Toxicology","raw_type":"journal-article"},{"id":"pmid:19040327","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19040327","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on drug metabolism & toxicology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[],"study_designs":[],"awards":[{"id":"https://openalex.org/G7045168795","display_name":"Amine N-Oxygenation by FMO3 and FMO4","funder_award_id":"R01DK059618","funder_id":"https://openalex.org/F4320337357","funder_display_name":"National Institute of Diabetes and Digestive and Kidney Diseases"}],"funders":[{"id":"https://openalex.org/F4320337357","display_name":"National Institute of Diabetes and Digestive and Kidney Diseases","ror":"https://ror.org/00adh9b73"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":41,"referenced_works":["https://openalex.org/W3650204","https://openalex.org/W1781980162","https://openalex.org/W1964976226","https://openalex.org/W1970543610","https://openalex.org/W1974993590","https://openalex.org/W1975091639","https://openalex.org/W1977998602","https://openalex.org/W1989360506","https://openalex.org/W1992346119","https://openalex.org/W1997442234","https://openalex.org/W2004651601","https://openalex.org/W2010547715","https://openalex.org/W2011013568","https://openalex.org/W2013159645","https://openalex.org/W2018159164","https://openalex.org/W2018614145","https://openalex.org/W2021604269","https://openalex.org/W2027224416","https://openalex.org/W2027816981","https://openalex.org/W2037169401","https://openalex.org/W2042849268","https://openalex.org/W2047038126","https://openalex.org/W2058735127","https://openalex.org/W2062002957","https://openalex.org/W2068390361","https://openalex.org/W2081056949","https://openalex.org/W2092213784","https://openalex.org/W2095385830","https://openalex.org/W2100536490","https://openalex.org/W2116393547","https://openalex.org/W2118180263","https://openalex.org/W2138685029","https://openalex.org/W2150524198","https://openalex.org/W2155201524","https://openalex.org/W2314145513","https://openalex.org/W2315739885","https://openalex.org/W2337128741","https://openalex.org/W2403105862","https://openalex.org/W2409188166","https://openalex.org/W2487080409","https://openalex.org/W2497438609"],"related_works":["https://openalex.org/W1489095888","https://openalex.org/W2590595176","https://openalex.org/W2073445887","https://openalex.org/W2352999168","https://openalex.org/W2403105862","https://openalex.org/W2525470835","https://openalex.org/W2018159164","https://openalex.org/W1970543610","https://openalex.org/W2027816981","https://openalex.org/W2155201524"],"abstract_inverted_index":{"This":[0],"review":[1],"summarizes":[2],"some":[3,64,110],"recent":[4],"observations":[5,111],"and":[6,36,45,55,76,96,116,122,140,151,170],"information":[7],"related":[8,143],"to":[9,28,144,166],"the":[10,13,29,86,90,101,124,137],"role":[11],"of":[12,34,49,92,103,114,126,136,163],"flavin-containing":[14],"monooxygenase":[15,22],"(FMO)":[16],"in":[17,66,72,94,106,120,130,156],"preclinical":[18,138],"drug":[19,95],"development.":[20],"Flavin-containing":[21],"is":[23],"a":[24],"complimentary":[25],"enzyme":[26],"system":[27],"cytochrome":[30],"P450":[31],"(CYP)":[32],"family":[33],"enzymes":[35],"oxygenates":[37],"several":[38],"soft,":[39],"highly":[40,56],"polarizable":[41],"nucleophilic":[42],"heteroatom-containing":[43],"chemicals":[44,117],"drugs.":[46],"The":[47],"products":[48],"FMO-mediated":[50],"metabolism":[51,98,113,129],"are":[52,70,146,153],"generally":[53],"benign":[54],"polar,":[57],"readily":[58],"excreted":[59],"materials.":[60],"There":[61],"may":[62],"be":[63],"advantages":[65],"designing":[67],"drugs":[68,115],"that":[69],"metabolized":[71],"part":[73],"by":[74,79,118],"FMO":[75,93,104,119,145],"not":[77,147],"exclusively":[78],"CYP.":[80],"In":[81],"this":[82],"review,":[83],"I":[84,160],"describe":[85],"practical":[87],"aspects":[88],"for":[89],"participation":[91],"chemical":[97],"including:":[99],"i)":[100],"study":[102],"using":[105],"vitro":[107],"preparations;":[108],"ii)":[109],"about":[112],"vivo;":[121],"iii)":[123],"consequences":[125],"studying":[127],"FMO-related":[128],"various":[131],"small":[132],"animal":[133],"models.":[134],"Some":[135],"research":[139],"development":[141],"areas":[142,150,165],"fully":[148],"mature":[149],"there":[152],"certain":[154],"gaps":[155],"our":[157],"knowledge.":[158],"However,":[159],"include":[161],"discussion":[162],"these":[164],"stimulate":[167],"further":[168,172],"work":[169],"invite":[171],"discussion.":[173]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1994057917","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":6},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":9},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":6},{"year":2012,"cited_by_count":6}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
